Bayer files Xarelto for new embolism indication
This article was originally published in Scrip
Executive Summary
Bayer has filed for expanded approval in the EU of its Factor Xa inhibitor Xarelto (rivaroxaban) for use in the initial treatment of pulmonary embolism (PE) and the prevention of recurrent deep vein thrombosis (DVT) and PE.